Results 211 to 216 of about 20,878 (216)

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Proceedings of the National Academy of Sciences of the United States of America, 2015
Idit Sagiv-Barfi, Ronald Levy
exaly  

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

Nature Communications, 2017
Dan A Landau, Clare Sun, Daniel Rosebrock   +2 more
exaly  

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Journal of Clinical Oncology, 2018
Steven P Treon, Joshua N Gustine, Guang Yang   +2 more
exaly  

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2015
Jan A Burger, Alessandra Tedeschi, Paul M Barr   +2 more
exaly  

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Journal of Clinical Oncology, 2013
Ranjana H Advani, Sonali M Smith, Nathan Fowler   +2 more
exaly  

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

Proceedings of the National Academy of Sciences of the United States of America, 2014
Rajarshi Guha, Ryan M Young, Adam Yasgar
exaly